Clinical Trials Using Pazopanib Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pazopanib Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-20 of 20
  • Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

    This randomized phase II / III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and / or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
    Location: 342 locations

  • A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA

    This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
    Location: 15 locations

  • Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

    The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, non rhabdomyosarcomatous soft tissue sarcoma, Ewing sarcoma, relapsed or refractory osteosarcoma, neuroblastoma (measurable and / or evaluable), or hepatoblastoma. This is a two-stage open label phase II trial of pazopanib in children, adolescents and young adults with recurrent or refractory solid tumors. Eligible subjects will receive pazopanib daily as an oral tablet (450 mg / m^2 / dose) or as a powder for suspension (225 mg / m^2 / dose) in 28 day cycles. The maximum dose to be administered daily for tablets is 800 mg and for suspension 400 mg. Subjects will be closely monitored with clinical and laboratory observations for side effects. Response to treatment will be evaluated using appropriate imaging studies. In the absence of severe toxicity or progressive disease, subjects may continue receiving pazopanib.
    Location: 13 locations

  • Pazopanib Hydrochloride as Front-Line Therapy in Treating Patients with Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery and Who Are Not Candidates for Chemotherapy

    This phase II trial studies how well pazopanib hydrochloride as front-line therapy (first treatment) works in treating patients with soft tissue sarcoma that has spread to other parts of the body or cannot be removed by surgery and who are not candidates for chemotherapy. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 8 locations

  • Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This randomized phase II trial studies how well gemcitabine hydrochloride with or without pazopanib hydrochloride works in treating patients with persistent or relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of epithelial ovarian, fallopian tube, or primary peritoneal cancer by blocking blood flow to the tumor or by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride together with pazopanib hydrochloride works better than giving gemcitabine hydrochloride alone in treating epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 8 locations

  • Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic Soft Tissue and Bone Sarcomas That Cannot Be Removed by Surgery

    This phase II trial studies how well pazopanib hydrochloride and topotecan hydrochloride work in treating patients with soft tissue and bone sarcomas that have from where it started to nearby tissue or lymph nodes or have spread to other places in the body and cannot be removed by surgery. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

    This phase I / II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with pancreatic neuroendocrine tumors (PNET) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) and cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be a better treatment for patients with PNET.
    Location: 5 locations

  • Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Recurrent Glioblastoma Multiforme

    This phase II trial studies how well pazopanib hydrochloride and topotecan hydrochloride work in treating patients with glioblastoma multiforme that has come back (recurrent). Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving low doses of pazopanib hydrochloride and topotecan hydrochloride daily may work better in treating patients with glioblastoma.
    Location: 4 locations

  • Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

    This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • Pazopanib Hydrochloride, Irinotecan, and Temozolomide in Treating Children and Young Adults with Relapsed or Refractory Sarcoma

    This phase I clinical trial studies the side effects and best dose of pazopanib hydrochloride when given together with irinotecan and temozolomide in treating children and young adults with sarcoma that has come back or does not respond to treatment. Pazopanib hydrochloride, irinotecan, and temozolomide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.
    Location: 2 locations

  • Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer

    The purpose of this study is to find out the effects, good and / or bad, of adding pazopanib (pazopanib hydrochloride) (the study drug) to current hormonal treatment (patients may take either anastrozole [Arimidex] or letrozole [Femara]). The study will see whether the combination is safe and easy to tolerate. If the study doctor is able to detect tumor cells in the blood before the treatment and / or during the treatment, he / she will also monitor the change of these tumor cells. Pazopanib is a drug taken by mouth that belongs to a class of medications called tyrosine kinase inhibitors. It works by slowing or stopping new blood vessel growth that can feed cancer growth.
    Location: 2 locations

  • Pazopanib Hydrochloride in Treating Molecularly Selected Patients with Advanced Non-small Cell Lung Cancer

    This pilot phase I trial studies pazopanib hydrochloride in treating molecularly selected patients with non-small cell lung cancer that has spread to other places in the body. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma

    This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is more effective with or without pazopanib hydrochloride in treating patients with soft tissue sarcoma.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer

    This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.
    Location: 3 locations

  • An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

    This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.
    Location: See Clinical Trials.gov

  • HDAC Inhibitor AR-42 and Pazopanib Hydrochloride in Treating Patients with Advanced Soft Tissue or Kidney Cancer

    This phase I trial studies how well histone deacetylase (HDAC) inhibitor AR-42 and pazopanib hydrochloride work in treating patients with soft tissue or kidney cancer that have spread to other places in the body and usually cannot be cured or controlled with treatment. HDAC inhibitor AR-42 and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This partially randomized phase I / II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 359 locations

  • Pazopanib Hydrochloride and Everolimus in Treating Patients with Advanced Solid Tumors or Previously Treated Advanced Urothelial Cancer

    This phase I trial studies the side effects and best dose of pazopanib hydrochloride and everolimus when given together in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment or previously treated urothelial cancer that has spread to other places in the body. Pazopanib hydrochloride and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Dynamic Contrast-Enhanced MRI and Ultrasound in Measuring Tumor Perfusion Changes in Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Receiving Pazopanib Hydrochloride

    All patients who participate in this study will receive pazopanib (pazopanib hydrochloride). Pazopanib is an oral drug (pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer. In this study, researchers plan to learn more about the way this drug works by using special scans (magnetic resonance imaging [MRIs] and ultrasounds) to help evaluate how this drug is working on kidney cancer.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania